Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itopride Hydrochloride 150mg Once Daily vs 50mg Thrice Daily in Functional Dyspepsia
NCT06217393Phase 3Completed
- Sponsor
- Abbott Laboratories
- Start
- Feb 2024
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial of itopride in functional dyspepsia (FD) and chronic gastritis (2 arms), sponsored by Abbott Laboratories. Primary endpoint: Leeds Dyspepsia Questionnaire Severity Score at 8 weeks. Started Feb 2024; status: completed.
02
Drugs
itopride
03
Conditions
functional dyspepsia (FD)chronic gastritis
Beyond the preview
Go deeper on NCT06217393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06217393.